Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 11.27% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Sep 25
Risky - Negative EBITDA
Underperformed the market in the last 1 year
Stock DNA
Healthcare Services
INR 31 Cr (Micro Cap)
NA (Loss Making)
56
0.00%
-2.30
35.41%
-11.92
Total Returns (Price + Dividend) 
Chennai Meena for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Chennai Meenakshi Multispeciality Hospital Faces Intense Selling Pressure Amid Market Volatility
Chennai Meenakshi Multispeciality Hospital has encountered significant selling pressure in recent trading sessions, with the stock registering no buying interest and only sell orders queued. This unusual market behaviour signals distress selling and raises concerns about investor sentiment towards the healthcare services provider.
Read More
Chennai Meenakshi Multispeciality Hospital Sees Unprecedented Buying Interest Amid Upper Circuit
Chennai Meenakshi Multispeciality Hospital has attracted extraordinary buying interest, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals strong investor enthusiasm and the potential for a multi-day circuit scenario, setting the healthcare services stock apart amid mixed sector and benchmark performances.
Read More
Chennai Meenakshi Multispeciality Hospital Sees Extraordinary Buying Interest Amid Upper Circuit Scenario
Chennai Meenakshi Multispeciality Hospital has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market activity signals a potential multi-day circuit scenario, reflecting strong demand despite recent price volatility and sector underperformance.
Read More Announcements 
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
12-Jan-2026 | Source : BSESub: Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 as amended for the quarter ended 31st December 2025. Based on the confirmation received from Cameo Corporate Services Limited Registrar and Share Transfer Agent of the Company we hereby certify that the securities received for dematerialization have been mutilated and cancelled after due verification and the name of the depository has been substituted in our records as the registered owner within the stipulated time limit under captioned regulations and the details are furnished to the stock exchange.
Appointment of Company Secretary and Compliance Officer
10-Jan-2026 | Source : BSEThis is further to our earlier announcement dated 9th January 2026 relating to the outcome of the Board Meeting held on 9th January 2026 and the appointment of Company Secretary and Compliance Officer pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the appointment of Ms. M.S. Anantha Lakshmi B. Com. C.M.A. M.B.A. A.C.S. C.A. (Inter). (holding Membership No. A46694) as Company Secretary and Compliance Officer of the Company has become effective from 9th January 2026. The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD-1/P/CIR/2023/123 dated 13th July 2023 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are provided in Annexure-A.
Appointment of Company Secretary and Compliance Officer
09-Jan-2026 | Source : BSEPursuant to regulation 30 of the SEBI (LODR) Regulations 2015 we wish to inform you that based on the recommendations of Nomination and Remuneration Committee and Audit Committee the board of Directors of the company at its meeting held today i.e. 9th January 2026 has approved the appointment of Ms. M.S. Anantha Lakshmi B. Com M.B.A. ACS. as Company Secretary and Compliance Officer of the Company with effect from 9th January 2026. The details as requested under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations 2015 are provided in the enclosed letter.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.14%)
Held by 0 FIIs
Jayanthi Radhakrishnan (25.59%)
Mahendra Girdharilal Wadhwani (2.65%)
39.83%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 9.48% vs -5.67% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 120.27% vs -338.71% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 7.73% vs -9.52% in Sep 2024
Growth in half year ended Sep 2025 is 44.34% vs -1,866.67% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is -10.50% vs 36.41% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -8,550.00% vs -96.88% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is -8.85% vs -1.39% in Mar 2024
YoY Growth in year ended Mar 2025 is -218.60% vs -148.31% in Mar 2024